Center-Authored Papers

Filters: Author is Baden, Lindsey R  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2010
Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, Gersten ID, Mendizabal AM, Leather HL, Confer DL et al..  2010.  Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.. Blood. 116(24):5111-8. Abstract
Cheng C, Gall JGD, Nason M, King RC, Koup RA, Roederer M, McElrath MJ, Morgan CA, Churchyard G, Baden LR et al..  2010.  Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization.. Journal of virology. 84(1):630-8. Abstract
Cooper CJ, Metch B, Dragavon J, Coombs RW, Baden LR.  2010.  Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients.. JAMA : the journal of the American Medical Association. 304(3):275-83. Abstract
2011
Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker L-G, McElrath MJ et al..  2011.  A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204).. PloS one. 6(8):e21225. Abstract
Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, Clark S, Ng'ang'a D, Brandariz KL, Abbink P et al..  2011.  International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.. Vaccine. 29(32):5203-9. Abstract
Baden LR, Blattner WA, Morgan C, Huang Y, Defawe OD, Sobieszczyk ME, Kochar N, Tomaras GD, McElrath MJ, Russell N et al..  2011.  Timing of Plasmid Cytokine (IL-2/Ig) Administration Affects HIV-1 Vaccine Immunogenicity in HIV-Seronegative Subjects.. The Journal of infectious diseases. 204(10):1541-1549. Abstract
2012
Kalams SA, Parker S, Jin X, Elizaga M, Metch B, Wang M, Hural J, Lubeck M, Eldridge J, Cardinali M et al..  2012.  Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults.. PloS one. 7(1):e29231. Abstract
2013
Barouch DH, Liu J, Peter L, Abbink P, Iampietro JM, Cheung A, Alter G, Chung A, Dugast A-S, Frahm N et al..  2013.  Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001).. The Journal of infectious diseases. 207(2):248-56. Abstract
Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, De Rosa S, Carter DK, Rybczyk K, Frank I et al..  2013.  Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery.. The Journal of infectious diseases. 208(5):818-29. Abstract
2014
Goepfert PA, Elizaga ML, Seaton K, Tomaras GD, Montefiori DC, Sato A, Hural J, De Rosa SC, Kalams SA, McElrath MJ et al..  2014.  Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles.. The Journal of infectious diseases. Abstract
Adenoviridae
Cheng C, Gall JGD, Nason M, King RC, Koup RA, Roederer M, McElrath MJ, Morgan CA, Churchyard G, Baden LR et al..  2010.  Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization.. Journal of virology. 84(1):630-8. Abstract
Adenoviridae Infections
Cheng C, Gall JGD, Nason M, King RC, Koup RA, Roederer M, McElrath MJ, Morgan CA, Churchyard G, Baden LR et al..  2010.  Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization.. Journal of virology. 84(1):630-8. Abstract
Adolescent
Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, Gersten ID, Mendizabal AM, Leather HL, Confer DL et al..  2010.  Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.. Blood. 116(24):5111-8. Abstract
Cooper CJ, Metch B, Dragavon J, Coombs RW, Baden LR.  2010.  Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients.. JAMA : the journal of the American Medical Association. 304(3):275-83. Abstract
Adult
Cooper CJ, Metch B, Dragavon J, Coombs RW, Baden LR.  2010.  Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients.. JAMA : the journal of the American Medical Association. 304(3):275-83. Abstract
Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, Gersten ID, Mendizabal AM, Leather HL, Confer DL et al..  2010.  Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.. Blood. 116(24):5111-8. Abstract
Aged
Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, Gersten ID, Mendizabal AM, Leather HL, Confer DL et al..  2010.  Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.. Blood. 116(24):5111-8. Abstract
AIDS Vaccines
Cooper CJ, Metch B, Dragavon J, Coombs RW, Baden LR.  2010.  Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients.. JAMA : the journal of the American Medical Association. 304(3):275-83. Abstract
Cheng C, Gall JGD, Nason M, King RC, Koup RA, Roederer M, McElrath MJ, Morgan CA, Churchyard G, Baden LR et al..  2010.  Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization.. Journal of virology. 84(1):630-8. Abstract
Antibodies, Neutralizing
Cheng C, Gall JGD, Nason M, King RC, Koup RA, Roederer M, McElrath MJ, Morgan CA, Churchyard G, Baden LR et al..  2010.  Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization.. Journal of virology. 84(1):630-8. Abstract
Antibody Specificity
Cheng C, Gall JGD, Nason M, King RC, Koup RA, Roederer M, McElrath MJ, Morgan CA, Churchyard G, Baden LR et al..  2010.  Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization.. Journal of virology. 84(1):630-8. Abstract
Antifungal Agents
Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, Gersten ID, Mendizabal AM, Leather HL, Confer DL et al..  2010.  Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.. Blood. 116(24):5111-8. Abstract
Antigens, Viral
Cheng C, Gall JGD, Nason M, King RC, Koup RA, Roederer M, McElrath MJ, Morgan CA, Churchyard G, Baden LR et al..  2010.  Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization.. Journal of virology. 84(1):630-8. Abstract
Aspergillosis
Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, Gersten ID, Mendizabal AM, Leather HL, Confer DL et al..  2010.  Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.. Blood. 116(24):5111-8. Abstract
August 2012
Pasquini MC, Devine S, Mendizabal A, Baden LR, Wingard JR, Lazarus HM, Appelbaum FR, Keever-Taylor CA, Horowitz MM, Carter S et al..  2012.  Comparative Outcomes of Donor Graft CD34+ Selection and Immune Suppressive Therapy As Graft-Versus-Host Disease Prophylaxis for Patients With Acute Myeloid Leukemia in Complete Remission Undergoing HLA-Matched Sibling Allogeneic Hematopoietic Cell Transpl. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(26):3194-201. Abstract